Uploaded November 2025 | Updated September 2026, 2 weeks ago
In this lecture, Dr. Mohamed Ali — Chief of Foregut, Metabolic and General Surgery at UC Davis Medical Center — explores how metabolic hormones such as GLP-1 are transforming the treatment of obesity. He discusses the biological basis of obesity as a chronic, relapsing disease, the science behind GLP-1 receptor agonists like semaglutide and tirzepatide, and how these medications compare to or complement bariatric surgery. Dr. Ali highlights the challenges of side effects, medication discontinuation, and weight recurrence, emphasizing the need for long-term, individualized treatment strategies. He also shares insights into how precision nutrition and combined surgical-pharmacologic approaches could shape obesity care and metabolic research in the future.
"The Science of Metabolic Hormones: Precision Nutrition in the 'Ozempic Era”' is a forum that took place at UC Davis' Sacramento campus on October 6-7, 2025. Guided by leading UC Davis researchers, the forum explored how deep scientific understanding of metabolic hormones like GLP-1s can inspire a new wave of innovation—shaping the future of food for health in meaningful, lasting ways.
Watch more lectures from this series: youtube.com/playlist?list=PLM7qvIv8N9Rs9ZS45aOkKzekHGnothOE4
Learn more about GLP-1 and health: https://health.ucdavis.edu/news/headlines/glp-1-and-health-beyond-weight-loss-in-the-ozempic-era/2025/11
UC Davis Center for Alimentary and Metabolic Science: https://health.ucdavis.edu/surgery/research/alimentary-metabolic/
UC Davis Innovation Institute for Food and Health: https://foodandhealth.ucdavis.edu/
See the latest news from UC Davis Health: https://health.ucdavis.edu/newsroom
This video includes an audio description track. To hear the narration of on‑screen text, turn on "English Descriptive" in the player’s settings menu.
-----
0:00 Introduction
1:18 Obesity as a chronic disease
2:40 Bariatric surgery
3:30 Semaglutide outcomes
4:32 Tirzepatide outcomes
4:59 Comparative efficacy
5:59 Patient experience limitations
8:48 Durability and weight recurrence
10:02 Surgery and medications together
12:21 Summary
The information in this video was accurate as of the recording date, 10/6/25. For information purposes only. Consult your local medical authority for advice.
#glp1 #glp1medications #ozempic #weightloss #ucdavis
In this lecture, Dr. Mohamed Ali — Chief of Foregut, Metabolic and General Surgery at UC Davis Medical Center — explores how metabolic hormones such as GLP-1 are transforming the treatment of obesity. He discusses the biological basis of obesity as a chronic, relapsing disease, the science behind GLP-1 receptor agonists like semaglutide and tirzepatide, and how these medications compare to or complement bariatric surgery. Dr. Ali highlights the challenges of side effects, medication discontinuation, and weight recurrence, emphasizing the need for long-term, individualized treatment strategies. He also shares insights into how precision nutrition and combined surgical-pharmacologic approaches could shape obesity care and metabolic research in the future.
"The Science of Metabolic Hormones: Precision Nutrition in the 'Ozempic Era”' is a forum that took place at UC Davis' Sacramento campus on October 6-7, 2025. Guided by leading UC Davis researchers, the forum explored how deep scientific understanding of metabolic hormones like GLP-1s can inspire a new wave of innovation—shaping the future of food for health in meaningful, lasting ways.
Watch more lectures from this series: youtube.com/playlist?list=PLM7qvIv8N9Rs9ZS45aOkKzekHGnothOE4
Learn more about GLP-1 and health: https://health.ucdavis.edu/news/headlines/glp-1-and-health-beyond-weight-loss-in-the-ozempic-era/2025/11
UC Davis Center for Alimentary and Metabolic Science: https://health.ucdavis.edu/surgery/research/alimentary-metabolic/
UC Davis Innovation Institute for Food and Health: https://foodandhealth.ucdavis.edu/
See the latest news from UC Davis Health: https://health.ucdavis.edu/newsroom
This video includes an audio description track. To hear the narration of on‑screen text, turn on "English Descriptive" in the player’s settings menu.
-----
0:00 Introduction
1:18 Obesity as a chronic disease
2:40 Bariatric surgery
3:30 Semaglutide outcomes
4:32 Tirzepatide outcomes
4:59 Comparative efficacy
5:59 Patient experience limitations
8:48 Durability and weight recurrence
10:02 Surgery and medications together
12:21 Summary
The information in this video was accurate as of the recording date, 10/6/25. For information purposes only. Consult your local medical authority for advice.
#glp1 #glp1medications #ozempic #weightloss #ucdavis
